J. Scherer

Double-Blind , Randomized Study Evaluating the Glycemic and Anti-in fl ammatory Effects of Subcutaneous LY 2189102 , a Neutralizing IL-1 b Antibody , in PatientsWith Type 2 Diabetes

E. Abu-Raddad, A. Gaetano, W. Landschulz, 2013 .

The genetics of common epilepsies: common or distinct? In The Lancet Neurology, the International League Against Epilepsy Consortium on Complex Epilepsies

D. Dodick, P. Goadsby, J. Scherer, 2014 .

Site of effect of LY2951742 for migraine prophylaxis–Authors' reply

D. Dodick, P. Goadsby, D. Grayzel, 2015, The Lancet Neurology.

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

D. Dodick, P. Goadsby, D. Grayzel, 2014, The Lancet Neurology.

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes

Andrea De Gaetano, A. De Gaetano, E. Abu-Raddad, 2013, Diabetes Care.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

D. Grayzel, E. Collins, A. van Hecken, 2017, Front. Pharmacol..

A decade of innovation in pharmaceutical R&D: the Chorus model

P. K. Owens, Paul K. Owens, Eyas Raddad, 2014, Nature Reviews Drug Discovery.

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study

D. Dodick, P. Goadsby, D. Grayzel, 2014, The Journal of Headache and Pain.